Mini-Tablet, Major Impact: From Lab to Commercial Scale
Republished from the official company website. Author and content source: Crystal Pharmatech.
Crystal Pharmatech’s integrated mini-tablet platform accelerates development from lab to commercial scale. We provide precision engineering, 505(b)(2) expertise, and high-precision filling for APIs.
Originally published by Crystal Pharmatech. Republished with company attribution. Original technical perspectives, references and source links are retained.
Mini-tablets are transforming complex drug delivery with unparalleled flexibility in dosing and release profiles. Yet scaling from lab concept to commercial production presents significant technical challenges—from achieving content uniformity at low drug loads to maintaining high-precision filling at manufacturing scale.
At Crystal Pharmatech, our integrated mini-tablet technology platform addresses these complexities head-on, delivering precision-engineered solutions from formulation development through commercial manufacturing.
Engineering Excellence: Our Technical Foundation
Our approach combines science-driven formulation with advanced process engineering:
Precision Formulation Development
We optimize material flow properties and particle size distribution (PSD) to achieve superior content uniformity, consistently meeting specifications at drug loads as low as 0.7%—a critical capability for potent APIs and pediatric formulations.
Compaction Simulation & Quality by Design
Leveraging compaction simulation technology, we optimize lubrication strategies and address high ejection forces early in development. Quality by Design (QbD) principles are embedded throughout our process, ensuring robust, scalable formulations.
Proprietary Equipment Modifications
We don't simply operate equipment—we optimize it. Our proprietary modifications to tableting presses eliminate common scale-up issues including chipping, breakage, and tablet defects, maximizing yield and reducing waste.
High-Precision Capsule Filling
Our filling systems achieve stable, reproducible filling of as few as 4 mini-tablets per capsule, meeting the most stringent industry standards for dose accuracy and consistency.
Comprehensive Equipment Capabilities Across Development Stages
R&D & Formulation Development
- Compaction simulators for material characterization
- Alexanderwerk WP120 for early-stage development
- Korsch XL100 with mini-tablet tooling
- Bonapace capsule filling systems
- Full suite of analytical characterization tools
Pilot Scale & Clinical Supply
- Alexanderwerk WP120 and WP200 roller compactors
- Korsch XL100 and X3 tablet presses
- Optimized Syntegon GKF 702 systems with specialized mini-tablet dosing units
- Freund Vector film coating systems
Commercial Manufacturing
- Alexanderwerk WP200 roller compaction
- Korsch XL400 presses equipped with mini-tablet modules
- Freund Vector coating systems for high-throughput production
- Seamless technology transfer protocols from pilot to commercial scale
Proven Track Record & Regulatory Expertise
Our core team brings deep mini-tablet expertise from leading 4+ major programs at multinational pharmaceutical companies. This experience provides a forward-thinking perspective on formulation challenges, scale-up considerations, and regulatory expectations.
Our Experience Spans:
- Early-stage R&D through IND filing
- Clinical supply manufacturing (Phase I-III)
- Successful FDA NDA submissions
- Pediatric indication development under 505(b)(2) pathway
Whether you're developing an innovative NCE or advancing a 505(b)(2) product with pediatric indications, Crystal Pharmatech's mini-tablet platform delivers the technical depth, manufacturing scale, and regulatory confidence required for success.
Ready to Discuss Your Mini-Tablet Program?
Contact our team to explore how our integrated platform can accelerate your development timeline and de-risk your path to commercialization.